People estimated with a nervous-system condition in 2021
Neurology
Finance specialized technology for neurologic care.
Specialized neurologic equipment needs a clear plan for the site, training, software, and service. We help vendors and buyers bring those details into the financing process.
01
Market pulse
The burden of nervous-system conditions is broad and growing more visible.
Research current through August 22, 2026
People in the U.S. reported with Alzheimer's disease
U.S. adults reported with active epilepsy
U.S. residents age 65 and older in 2024
A 2025 peer-reviewed analysis of Global Burden of Disease 2021 data estimated that 180.3 million people in the United States,54.2% of the population,had at least one of 36 conditions affecting nervous-system health in 2021. The analysis attributed 16.6 million disability-adjusted life-years to those conditions.
The CDC reports that nearly 7 million people in the United States have Alzheimer's disease. It also estimates that 2.9 million U.S. adults had active epilepsy in 2021,2022. The National Institute of Neurological Disorders and Stroke estimates that Parkinson's disease affects between 500,000 and 1 million people in the United States.
Demographics reinforce the need for capacity planning. The U.S. population age 65 and older reached 61.2 million in 2024, up 3.1% in one year.
Nervous-system health burden, U.S.
54.2%Share with at least one covered condition
180.3MPeople represented
16.6MDisability-adjusted life-years
Reported U.S. prevalence, selected conditions
~7MAlzheimer’s disease
2.9MActive epilepsy
0.5–1MParkinson’s disease
What the data means for equipment decisions
The category matters. The specific operating decision matters more.
Neurology technology can support diagnosis, monitoring, treatment, neuromodulation, rehabilitation, surgical planning, research, or patient support. Each use may involve different providers, credentials, protocols, contraindications, software, service, and regulatory requirements.
The buyer may be a physician practice, specialty clinic, hospital, rehabilitation facility, academic center, research organization, behavioral-health provider, or multi-site group. The seller should identify the intended clinical program and accountable operators before discussing a payment structure.
Financing can organize an eligible equipment purchase. It cannot establish clinical appropriateness, patient selection, regulatory compliance, treatment response, reimbursement, demand, or program readiness. Those decisions remain with the qualified clinical, regulatory, operating, and contracting parties.
03
Complete scope
The complete equipment investment
Include installation, software, training, and service in the purchase discussion so costs are clear from the start.
- 01
EEG, EMG, nerve-conduction, evoked-potential, and related diagnostic systems
- 02
TMS, neurostimulation, neuromodulation, and other treatment platforms
- 03
Monitoring, seizure detection, cognitive assessment, movement analysis, and patient-support technology
- 04
Navigation, imaging integration, treatment planning, robotic, and procedure-support systems
- 05
Neurologic rehabilitation, balance, gait, mobility, stimulation, and recovery equipment
- 06
Software, workstations, data storage, reporting, interfaces, cybersecurity, and updates
- 07
Chairs, positioning, patient monitoring, accessories, disposables, and room equipment
- 08
Delivery, site preparation, installation, calibration, training, validation, warranty, and service
The quote should separate primary equipment, required accessories, software, recurring services, facility work, and costs outside the request. Eligibility remains subject to review.
Where financing fits
Plan financing around the technology and intended use.
Financing may help a buyer compare an upfront purchase with an approved obligation paid over time. It does not prove that a clinical program will enroll patients, receive reimbursement, achieve outcomes, reach utilization targets, or generate a return.
The equipment and program context should be clear:
01
Replacement
Updating an existing diagnostic, monitoring, or treatment system.
02
Capacity
Adding equipment to an established neurologic service.
03
New clinical program
Introducing a treatment, diagnostic, or rehabilitation capability.
04
New site or team
The equipment depends on facility, staffing, credentials, protocols, and launch.
05
Research or institutional use
Procurement, contracting, intended use, and acceptance may involve additional parties.
05
Vendor discovery
What the vendor sales team should clarify
Better questions create a cleaner handoff without turning a representative into a credit expert.
- 01
What is the device's intended use, and which clinical program will support it?
- 02
Which legal entity is buying, and where will the system operate?
- 03
Is the purchase replacement, added capacity, a new program, a new site, or institutional use?
- 04
Which equipment, accessories, software, training, warranty, service, and recurring items are included?
- 05
Who will operate the technology, and what credentials, protocols, supervision, or training apply?
- 06
What room, electrical, network, cybersecurity, installation, calibration, or safety requirements apply?
- 07
Who owns clinical readiness, patient workflow, installation, validation, and acceptance?
- 08
Which patient-volume, reimbursement, response, clinical, or revenue figures are assumptions rather than guaranteed results?
A responsible LeasePoint workflow
Connect specialized equipment sales with financing support.
See how sellers, buyers, and LeasePoint work together from introduction through final requirements.
01
Define the clinical and equipment context
Capture the buyer, site, intended use, complete quote, responsible team, target timing, and implementation dependencies.
02
Move the buyer into the secure finance process
LeasePoint owns the appropriate application, credit, possible structures, documentation, and transaction questions.
03
Preserve the boundaries that matter
Coordinate permitted milestones while clinical judgment, patient information, regulatory obligations, device performance, restricted applicant data, and final finance decisions remain with their authorized owners.
07
Frequently asked questions
Questions that deserve a direct answer.
Focused guidance for sellers and buyers evaluating a complete equipment purchase.
What neurology equipment may be considered?+
Programs may be designed around diagnostic, monitoring, neuromodulation, treatment, rehabilitation, software, and supporting technology. Eligibility depends on the device, intended use, seller, buyer, project, structure, documentation, and review.
Can equipment for a new clinical program be financed?+
The equipment can enter the applicable review, but the new-program context should be clear. Provider credentials, protocols, patient workflow, site readiness, training, service, operating evidence, and complete costs may affect the information required.
Does financing validate clinical appropriateness or patient demand?+
No. Financing addresses how an eligible purchase may be paid for. Patient selection, clinical appropriateness, treatment response, demand, reimbursement, utilization, and outcomes remain separate determinations.
Can software, training, and service be included?+
They should appear clearly when part of the complete system. Whether each cost can be included is determined during review. Recurring subscriptions, upgrades, disposables, and third-party services may need separate treatment.
What happens when the clinical program or system scope changes?+
Return the revised quote and project context through the approved workflow. Changes to equipment, amount, intended use, site, ownership, seller, services, delivery, or acceptance may require additional review and updated documents.
Source register
Evidence behind the market context.
Research current through August 22, 2026. Statistics provide market context, not a forecast for an individual company, practice, project, or financing decision.
- 01U.S. Burden of Disorders Affecting the Nervous System: From the Global Burden of Disease 2021 Study
- 02About the Alzheimer's Disease Program
- 03Epilepsy Facts and Stats
- 04Parkinson's Awareness Month: Research, Progress, and a National Commitment to End Parkinson's Disease
- 05Older Adults Outnumber Children in 11 States and Nearly Half of U.S. Counties